OrbusNeich   Report issue

For profit Phase 4
Founded: Hong Kong China (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2011
NCT01394848
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

OrbusNeich

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Angina, Unstable (Phase 4)

Coronary Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 6